AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 249 filers reported holding AMICUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,926 | -2.6% | 1,474,173 | +0.6% | 0.03% | +8.3% |
| Q2 2023 | $18,411 | +10.3% | 1,465,864 | -2.6% | 0.02% | +9.1% |
| Q1 2023 | $16,687 | -12.4% | 1,504,718 | -3.5% | 0.02% | -15.4% |
| Q4 2022 | $19,043 | -99.9% | 1,559,601 | +26.2% | 0.03% | +36.8% |
| Q3 2022 | $12,897,000 | -2.7% | 1,235,353 | +0.0% | 0.02% | +11.8% |
| Q2 2022 | $13,261,000 | +14.6% | 1,234,746 | +1.0% | 0.02% | +41.7% |
| Q1 2022 | $11,572,000 | -18.0% | 1,221,951 | +0.0% | 0.01% | -14.3% |
| Q4 2021 | $14,111,000 | +61.4% | 1,221,752 | +33.4% | 0.01% | +55.6% |
| Q3 2021 | $8,743,000 | -4.4% | 915,524 | -3.5% | 0.01% | 0.0% |
| Q2 2021 | $9,150,000 | -3.2% | 949,174 | -0.8% | 0.01% | -10.0% |
| Q1 2021 | $9,456,000 | +58.3% | 957,077 | +270.1% | 0.01% | +42.9% |
| Q4 2020 | $5,972,000 | +77.8% | 258,620 | +8.8% | 0.01% | +75.0% |
| Q3 2020 | $3,358,000 | -5.7% | 237,800 | +0.7% | 0.00% | -20.0% |
| Q2 2020 | $3,560,000 | +67.8% | 236,100 | +2.8% | 0.01% | +66.7% |
| Q1 2020 | $2,122,000 | -5.1% | 229,700 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $2,237,000 | +7.5% | 229,700 | -11.4% | 0.00% | 0.0% |
| Q3 2019 | $2,080,000 | -29.7% | 259,400 | +9.4% | 0.00% | -25.0% |
| Q2 2019 | $2,960,000 | +17.3% | 237,200 | +27.8% | 0.00% | +33.3% |
| Q1 2019 | $2,524,000 | +42.0% | 185,600 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $1,778,000 | -33.6% | 185,600 | -16.1% | 0.00% | 0.0% |
| Q3 2018 | $2,676,000 | -22.3% | 221,325 | +0.3% | 0.00% | -25.0% |
| Q2 2018 | $3,446,000 | +9.3% | 220,625 | +5.2% | 0.00% | 0.0% |
| Q1 2018 | $3,154,000 | +30.9% | 209,725 | +25.3% | 0.00% | +33.3% |
| Q4 2017 | $2,409,000 | -3.3% | 167,425 | +1.4% | 0.00% | 0.0% |
| Q3 2017 | $2,491,000 | +61.1% | 165,166 | +7.6% | 0.00% | +50.0% |
| Q2 2017 | $1,546,000 | +52.9% | 153,500 | +8.3% | 0.00% | +100.0% |
| Q1 2017 | $1,011,000 | +43.4% | 141,801 | +0.0% | 0.00% | 0.0% |
| Q4 2016 | $705,000 | -32.8% | 141,800 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $1,049,000 | +28.1% | 141,800 | -5.5% | 0.00% | +100.0% |
| Q2 2016 | $819,000 | -14.4% | 150,028 | +32.4% | 0.00% | 0.0% |
| Q1 2016 | $957,000 | -12.9% | 113,300 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $1,099,000 | -30.7% | 113,300 | 0.0% | 0.00% | -33.3% |
| Q3 2015 | $1,585,000 | +79.1% | 113,300 | +81.1% | 0.00% | +200.0% |
| Q2 2015 | $885,000 | – | 62,570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |